InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune ...

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- ...

Looking at options history for Moderna (NASDAQ: MRNA) we detected 22 trades. If we consider the specifics of each trade, it ...

Overview: Sandisk has delivered a 172.8% return in early 2026, showing how rising global data creation and storage demand are ...

Cryogenic plays Cryosite and Vitrafy Life Sciences have had a warm start to the year, on the back of soaring ... Read More The post Health Check: Cryogenic stocks come in from the cold appeared first ...

Merck's blockbuster immunotherapy Keytruda, which generates nearly half of its total revenue, is scheduled to lose U.S. patent protection in 2028, opening the door to lower-cost generic competition.

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position ...

The drug and biotech sector has recovered somewhat in 2026 after remaining muted for most of 2025. Drug pricing agreements of ...

Moderna, Inc. (NASDAQ: MRNA) shares are swinging in volatile early trading on Friday, February 27, 2026, as investors digest ...

Agilent Technologies Inc. reports fiscal first-quarter earnings after the market close Wednesday, with analysts watching for signs that a recovering pharmaceutical and biotech market can ...